Limiting GLP-1 coverage may be linked to reduced employee satisfaction, increased burnout, and greater turnover risk, leaving benefits leaders with a difficult and urgent challenge: how to help more patients succeed with GLP-1s while managing clinical complexity, patient experience, and financial sustainability. Our latest GLP-1 patient survey uncovers four critical themes to consider when solving this dilemma: ✅️ Does your population have access to judgement-free obesity care? ✅️ Is there a clear care plan for patients after they’ve discontinued a GLP-1, so they can avoid weight regain? ✅️ Are rising out‑of‑pocket costs and coverage limits becoming a substantial burden on your population, impacting wellbeing and productivity? ✅️ Once the patient is prescribed a GLP-1, do they have between-visit support for nutrition, exercise, behavior change, and medication adherence? Read our 2026 GLP-1 patient survey to learn more: https://lnkd.in/dpNQNvYQ
Raise your hand if you’re in Las Vegas for #AHIP2026! Swing by booth 1424 to meet our team and hear how we’re connecting cardiometabolic care across one integrated platform—now expanded to include GLP-1 prescribing and specialized cholesterol care. Plus, we’re scheduling 1:1 convos at our in-booth Innovation Lounge to dig into the tough issues surrounding care fragmentation and cost. Stop on by, say hello, and sign up for a 1:1 strategy session!
📑 A signed contract should mean a patient can find their virtual care provider, reach them, and have the claim paid. What really happens 👉 Providers end up in network on paper but out of reach in practice. With CMS raising the bar for provider directory accuracy and transparency, and payers expanding contracting with virtual-first care providers, we need to ensure that providers are fully integrated, discoverable, and reimbursable for patients. DiMe's Post-Contracting Operational Readiness for Virtual-First Care project, with Omada Health as title sponsor, will convene payers, virtual-first care providers, and policy advisors to build a shared standard for what it takes to go from a signed contract to a provider patients can actually use. 🩺 This builds on our Virtual-First Care Coalition, whose contracting toolkit cut time to contract by up to 18 months. Now we're carrying that progress past the signature and into care delivery. We're grateful to Omada Health for leading as title sponsor and to the founding partners shaping this work. We're welcoming additional partners! Learn more and get involved: https://lnkd.in/dBbsNar2
Is GLP-1 weight loss mostly body fat or muscle mass? And does it even matter? Our new 12-week study looked at how body composition changes when people lose weight on GLP-1s, and if Omada’s nutrition and exercise support can help optimize body composition. Read the results here: https://lnkd.in/dUUrZQq9
Last summer, we celebrated our IPO with a bell-ringing ceremony at Nasdaq headquarters surrounded by family, friends and fellow Omadans. One year later, we may be sentimental, but we're not satisfied. Going public set real change in motion. It has strengthened an already solid financial position and expanded our reach. We've grown to serve more than 2 million members nationwide––and counting. But what hasn't changed is our ambition and our focus. As our CEO Sean Duffy said that day, "It’s a chance to truly swing big and dream big toward helping many tens of millions and to bend the curve of chronic disease.” We continue to partner with leading employers, PBMs and health plans, and to support our members living with obesity and other chronic diseases. Our evidence-based treatment plans, multi-disciplinary care teams, and AI-enhanced insights help us achieve industry-leading clinical outcomes, including in the GLP-1 space. As our footprint grows, so does our responsibility—and our determination—to deliver results that matter, including better outcomes, lower costs, and the trust of our partners and members. Becoming a public company was never the mission. It was a milestone on the way to deepening our impact—because the challenge we’re working to solve hasn’t changed, and our commitment to solving it is only getting stronger. We’re here to bend the curve of chronic disease, one day at a time. #CelebrateOMDA
You might be wondering, why is a diabetes, weight and heart health provider like Omada talking about kidney disease? Because the American Heart Association's cardiovascular-kidney-metabolic (CKM) health initiative explicitly frames heart disease, kidney disease, diabetes, and obesity as part of a shared syndrome requiring coordinated care. In our latest edition of Proof Points, Senior Clinical Research Scientist Susan Devaraj PhD, RD highlights how many of the same behaviors that protect the heart and help manage blood sugar can also protect the kidneys: She digs into: → Why early kidney disease risk identification should sit alongside diabetes, obesity, and hypertension care. → How lifestyle support that improves blood pressure, glycemic control, and weight can meaningfully reduce kidney disease risk. → The role of scalable, between-visit virtual care in closing equity gaps for high‑risk populations. If you’re responsible for benefits design or population health strategy, this is a must‑read. 👇
3,000+ GLP-1 patients just told us what’s working, what’s breaking, and what they wish their employers understood. Explore one of the largest GLP-1 patient surveys of its kind and see the must-know insights for your population strategy. https://lnkd.in/dpNQNvYQ
You read that right. In our latest 12-week comparative study on body composition and GLP-1s, the group who received Omada’s support reported greater improvements in lifestyle change, physical function, and confidence in their ability to lose weight. Want to see what else our study uncovered? Read the full white paper now. https://lnkd.in/dUUrZQq9
Join Horizon Day 2026 for a LinkedIn Live reveal of how Omada is redefining cardiometabolic care as GLP-1s reshape the obesity treatment landscape. As new medication options rapidly transform how we approach obesity—and concerns around access, cost, and fragmentation rise just as quickly—it’s never been more important to connect the dots across the care continuum. Be among the first to see how our latest advancements—GLP-1 prescribing capabilities, GLP-1 Flex Care benefit design, and targeted cholesterol support—come together to connect those dots, delivering continuous, whole-person cardiometabolic care. You’ll walk away with a clear view of what this means for benefit strategies, clinical outcomes, and the member experience. Don't miss Omada's Sean Duffy and Wei-Li Shao as they showcase Omada’s integrated approach, including a walk-through of GLP-1 prescribing and the guided medication care experience. They'll also reveal the strategy and vision shaping the future of Omada's care model. We’ll be taking audience Q&A in real time during the event, so join us—and join the conversation.
Omada Health is proud to be Certified™ by Great Place To Work® for the 3rd year in a row. The prestigious award is based entirely on what current employees say about their experience working at Omada. This year, 86% of employees said it’s a great place To Work – 29% higher than the average U.S. company. Great Place To Work® is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. Read more about our award here: https://www.greatplacetowork.com/certified-company/7022924
